Poly-Med opens a new 30,000sf state-of-the-art facility dedicated to expanding manufacturing and development demands. This new facility allows for more than double the manufacturing capabilities at Poly-Med.
All timeline stories.
Our company remains focused on the advancement of material solutions for medical device and drug delivery applications.
In order to meet the increasing need for specialty engineering and manufacturing support, we are expanding. Our new state-of-the art facility will include additional offices and manufacturing areas for engineering, quality assurance, polymerization, textile conversion, and packaging.
A molded fastener used for soft tissue fixation prepared from our Max-Prene® 955, is cleared for marketing. This marks the 15th product utilizing Poly-Med’s bioabsorbable technologies released into the marketplace.
In continuing support of Clemson University’s increased graduate student research and education, Poly-Med Inc. proudly employs three adjunct faculty professors.
Dr. Shalaby is awarded the Society for Biomaterials, C. William Hall lifetime achievement award. This esteemed award honors significant contributions to biomaterials science and education.
The first sustained release pharmaceutical, utilizing a proprietary Poly-Med polymer system, is officially launched in Germany. The polymeric base provides a stable, hydro-setting gel system to release the antibiotic doxycycline for 14 days.
Highlighting Poly-Med, Inc.’s vertically integrated capabilities, the first hernia mesh utilizing our specialized polymers, extrusion, and knitting technologies is launched.
Our 100th patent application is submitted to the USPTO. US Patent 7,632,765 is granted from this application, disclosing inorganic-organic melted extruded fibers and constructs for use in advanced medical devices.
Poly-Med opens a 14,000sf state-of-the-art facility dedicated to expanding manufacturing and quality demands. This new facility allows for more than double the manufacturing capabilities.